Bjorn L. Frendeus

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.

Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 30, 2026

Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity.

Ligand-Blocking and Agonist Antibodies Targeting TNFR2 Employ Distinct Modes of Action to Induce Antitumor Immunity.

Journal: Cancer research

Published: January 16, 2026

Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling.

Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling.

Journal: Immunity

Published: July 02, 2025

A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.

A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 15, 2025

FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs.

FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs.

Journal: Clinical and experimental immunology

Published: December 03, 2024

A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for Immunotherapy.

A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for Immunotherapy.

Journal: Cancer immunology research

Published: November 04, 2024

Human leukocyte immunoglobulin-like receptors in health and disease.

Human leukocyte immunoglobulin-like receptors in health and disease.

Journal: Frontiers in immunology

Published: August 25, 2023

Sequence enrichment profiles enable target-agnostic antibody generation for a broad range of antigens.

Sequence enrichment profiles enable target-agnostic antibody generation for a broad range of antigens.

Journal: Cell reports methods

Published: September 27, 2022

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.

FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.

Journal: Cell reports

Published: February 20, 2022

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.

Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors.

Journal: Journal for immunotherapy of cancer

Published: December 27, 2021

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.

Journal: Journal of hematology & oncology

Published: December 23, 2021

HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.

HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.

Journal: Journal of experimental & clinical cancer research : CR

Published: October 04, 2021

Showing 1-12 of 34

Last Updated: 09/26/2026